Co-Diagnostics director granted 1,695 CODX shares
Co-Diagnostics, Inc. director Richard S. Serbin reported equity compensation activity involving restricted stock units.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Co-Diagnostics, Inc. director Richard S. Serbin reported equity compensation activity involving restricted stock units. On May 23, 2026, he acquired 1,695 shares of Common Stock at $0.00 per share through a grant and related RSU conversion, rather than an open‑market purchase. After this transaction, he directly holds 10,751 Common shares and 4,000 restricted stock units. The footnotes explain these RSUs were awarded under the company’s 2015 Long Term Incentive Plan with scheduled vesting in six semiannual installments across multiple grant dates.
Insider Trade Summary
1,695 shares exercised/converted
Exercise
2 txns
Insider
SERBIN RICHARD S
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 1,695 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 1,695 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Unit — 4,000 contracts (Direct);
Common Stock — 10,751 shares (Direct)
Footnotes (1)
- F1. Included in 2,334 restricted stock units awarded to the Reporting Person on June 12, 2023, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2023. Included in 3,667 restricted stock units awarded to the Reporting Person on April 26, 2024, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2024. Included in 4,167 restricted stock units awarded to the Reporting Person on August 13, 2025, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2025.
Key Figures
Shares acquired: 1,695 shares
Price per share: $0.00 per share
Shares held after: 10,751 shares
+3 more
6 metrics
Shares acquired
1,695 shares
Common Stock grant and RSU conversion on May 23, 2026
Price per share
$0.00 per share
Equity compensation, not open-market purchase
Shares held after
10,751 shares
Total direct Common Stock holdings following transaction
RSUs exercised
1,695 units
Restricted Stock Units converted to Common Stock
RSUs remaining
4,000 units
Restricted Stock Units outstanding after the exercise
Underlying RSU shares
5,695 shares
Common Stock underlying reported restricted stock units
Key Terms
Restricted Stock Unit, Long Term Incentive Plan, derivative security
3 terms
Restricted Stock Unit financial
"Included in 2,334 restricted stock units awarded to the Reporting Person on June 12, 2023"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Long Term Incentive Plan financial
"pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan"
A long term incentive plan is a company program that awards executives and key employees bonuses—often in stock, options, or cash—only if the business meets multi-year performance goals. It links management pay to company results—like tying a coach’s bonus to a team’s multi-season record—so investors monitor it for how leaders are motivated, potential share dilution, and signals about the company’s long-term priorities.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CODX director Richard Serbin report?
Director Richard Serbin reported acquiring 1,695 Co-Diagnostics (CODX) common shares via equity compensation. The shares came from a restricted stock unit grant and conversion, not an open-market purchase, and were recorded at a price of $0.00 per share.
Was the CODX insider transaction a market purchase or a compensation grant?
The CODX insider transaction reflects equity compensation, not a market purchase. Richard Serbin received 1,695 common shares at $0.00 per share through a grant and conversion of restricted stock units awarded under the company’s 2015 Long Term Incentive Plan.
What derivative activity involving CODX restricted stock units was reported?
The filing shows an exercise of 1,695 restricted stock units into Co-Diagnostics (CODX) common shares. After this derivative exercise, 4,000 restricted stock units remain outstanding, while 5,695 underlying common shares are tied to these RSU awards under the incentive plan.
How are CODX restricted stock units for Richard Serbin scheduled to vest?
Footnotes state that Serbin’s CODX restricted stock units were granted in 2023, 2024, and 2025 under the 2015 Long Term Incentive Plan. Each grant vests in six equal installments every six months, beginning on November 23 of the year specified for each award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
